Posts Tagged ‘Pfizer’

[Perspective] Why Pfizer Implemented Oracle CTMS in the Cloud

Many companies in the life sciences industry experience rapid global growth, both organically as well as through merger and acquisition. While growth is, of course, great and welcome, it also comes with some challenges. With respect to clinical operations and clinical trial management, aligning processes can be rather challenging as different parts of the business […]

Cloud CTMS for Pfizer

[Perspective] A Cloud CTMS Was a Requirement for Pfizer

While Pfizer’s IT team had been supporting the legacy CTMS and other clinical systems for many years, the company’s current strategy centers on implementing cloud solutions. The reason for this approach is to reduce the burden on internal resources and reduce the need to invest in IT infrastructure. Having different, nuanced processes and decentralized data […]

Acceptability Equals Mobility

The Case For Involving Treating Physicians In Subject Recruitment

Clinical Leader recently published an article in which the author and a representative of Pfizer made some really interesting points about the role of treating physicians in clinical subject recruitment. The typical approach to recruitment is to target patients directly. On the surface, this approach may seem patient- or customer-centric, but when you look a […]

Shared Investigator Platform (SIP) Strengths And Struggles

At any given time, a principal investigator (PI) can be working on one or more studies for a single sponsor company, or multiple studies for multiple sponsors. Likewise, each sponsor runs its clinical trials its own way, using its preferred technology and processes. And, often times, the technology and/or processes differ from study to study, […]

How Pharma Executives View Drug Pricing

The cost and affordability of drugs has been a central theme permeating the pharmaceutical industry for decades. Drugs are believed to be too expensive for patients to cover at the counter, even for those who are insured. The sentiment shared is by both Republicans and Democrats. The high cost of drugs can have significant repercussions, […]

How Bad Trade Policy Impacts Pharma

The United States is known for massive innovation across sectors, especially in the pharmaceutical arena. According to the Pharmaceutical Research and Manufacturers of America, in 2015 member companies of the advocacy organization invested more than $58 billion in research and development, making the pharmaceutical industry the largest investor in research and development of any sector. […]

The Case For A Reformed FDA

Life sciences is one of the most heavily regulated industries in the United States. It takes 10 to 15 years and an average of $2.6 billion for a drug to reach pharmacy shelves. Stringent regulations formed by the FDA are major factors for the lengthy timelines and high costs, sometimes preventing people from receiving potentially […]

Why Pharma Execs Want A More Favorable Tax Climate

The idea of companies moving their businesses to other parts of the world to benefit from lower taxes is not new. Allergan, the maker of Botox® and other drugs, transferred its global headquarters from New Jersey to Ireland in 2013. Medtronic moved its headquarters to Ireland in 2015, once it completed the acquisition of Covidien, […]

Top 10 Life Sciences Blog Posts Of 2016

While we rolled into 2017, I thought it would be neat to see what our readers were, well, reading. Without further ado, here are the top 10 blog posts Perficient’s life sciences practice wrote that seemed to be popular among readers. They’re ranked in order of popularity, with number one being the most viewed piece. The 8 […]

Top 5 Life Sciences Blog Posts From August 2016

Now that September is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in August – they’re ranked in order of popularity, with number one being the most viewed piece. Pfizer, Eli Lilly, And Roche […]

Pfizer, Eli Lilly, And Roche Speak On Using Digital Health Tools

At this year’s MedCity CONVERGE, a two-day summit in which executives convene to discuss the future of innovation in healthcare and life sciences, digital was a hot topic. In a presentation titled “Digital Health’s Arrival (Or Not) In Pharma,” Dr. Naomi Fried, an expert on digital health innovation and past chief innovation officer at Boston […]

Top 5 Life Sciences Blog Posts From July 2016

Now that August is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in July – they’re ranked in order of popularity, with number one being the most viewed piece. When Do Companies Have To […]

Load More